A pre-clinical study, conducted by Amanda LoGuidice, University of Florida, USA, has shown that multipotent adult progenitor cells on an allograft scaffold can facilitate the bone repair process. The research has recently been published in the Journal of Tissue Engineering.
The study is the first peer-reviewed, published pre-clinical study comparing multipotent adult progenitor cells to mesenchymal stem cells in bone healing.
The study showed multipotent adult progenitor cells to exhibit a more robust angiogenic protein release profile compared to mesenchymal stem cells in vitro. In addition, multipotent adult progenitor cells demonstrated enhanced revascularisation and new bone formation in vivo in an orthotopic defect model, when compared to mesenchymal stem cells when placed on a demineralised bone matrix scaffold.
According to a press release from RTI Surgical, the study used similar materials to the company’s proprietary, patented multipotent adult progenitor cell-based technology, used in the map3 cellular allogeneic bone grafts.
“We value research that helps us continue to provide surgeons with safe, high-quality implants,” says Carrie A Hartill, executive vice president and chief scientific officer of the company.
